Candel presents second enLIGHTEN candidate at AACR; induces TLS, enhances anti-PD-1 in mice

Candel Therapeutics, Inc.

Second multimodal immunotherapy candidate from enLIGHTEN platform targets tertiary lymphoid structures (TLS) in solid tumors.
Two payload combinations, predicted via enLIGHTEN analytics, induced TLS, monotherapy anti-tumor activity, and boosted anti-PD-1 response in mouse models.
Milestone accelerated from Q3 2024 to April 2024, validating platform speed.
TLS induction is a novel strategy to improve anti-tumor immunity; data presented at AACR April 5-10, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.